dc.contributorUniversidade Estadual Paulista (UNESP)
dc.creatorPinheiro, O. L.
dc.creatorCavagna, M.
dc.creatorBaruffi, RLR
dc.creatorMauri, A. L.
dc.creatorPetersen, C.
dc.creatorFranco, J. G.
dc.date2014-05-20T13:35:07Z
dc.date2016-10-25T16:52:36Z
dc.date2014-05-20T13:35:07Z
dc.date2016-10-25T16:52:36Z
dc.date2003-12-01
dc.date.accessioned2017-04-05T20:27:49Z
dc.date.available2017-04-05T20:27:49Z
dc.identifierJournal of Assisted Reproduction and Genetics. New York: Kluwer Academic/plenum Publ, v. 20, n. 12, p. 513-516, 2003.
dc.identifier1058-0468
dc.identifierhttp://hdl.handle.net/11449/12064
dc.identifierhttp://acervodigital.unesp.br/handle/11449/12064
dc.identifier10.1023/B:JARG.0000013652.17193.38
dc.identifierWOS:000188532000006
dc.identifierhttp://dx.doi.org/10.1023/B:JARG.0000013652.17193.38
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/859728
dc.descriptionPurpose: the objective of the present investigation was to determine implantation and pregnancy rates in patients undergoing ICSI and treated with beta(2)-adrenergic agonists, considering the uterine-relaxing action of these agents.Methods: A total of 225 women undergoing ICSI at the Center for Human Reproduction, Sinha Junqueira Maternity Foundation, entered the study. Patient participation in each group was random, by drawing lots, using a randomization table previously elaborated for the study (2:2:1). The group I (90 women) received 10 mg of terbutaline daily for 15 days starting on the day of oocyte retrieval; group II (90 women) received 20 mg of ritodrine daily during the same period of time as group I; group III (45 patients) received no treatment and was used as control. The evaluation was interrupted in 3 patients of group I and in 30 patients of group II because of a high incidence of side effects.Results: Pregnancy, implantation, and miscarriage rates were not significantly different (p>0.05) between the three groups: 29.88%, 13.25%, and 26.9% for group I; 33.33%, 17.5%, and 10.0% for group II; 28.88%, 15.07%, and 15.38% for group III, respectively.Conclusions: the results of this study do not support the routine use of beta(2)-adrenergic agonists during the peri-implantation period in assisted reproductive technology cycles.
dc.languageeng
dc.publisherKluwer Academic/plenum Publ
dc.relationJournal of Assisted Reproduction and Genetics
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectICSI
dc.subjectimplantation rates
dc.subjectritodrine
dc.subjectterbutaline
dc.subjectuterine contractility
dc.titleAdministration of beta(2)-adrenergic agonists during the peri-implantation period does not improve implantation or pregnancy rates in intracytoplasmic sperm injection (ICSI) cycles
dc.typeOtro


Este ítem pertenece a la siguiente institución